Chemistry:Nelarabine

From HandWiki
Short description: Chemical compound
Nelarabine
Nelarabine structure.svg
Nelarabine ball-and-stick.png
Clinical data
Trade namesArranon, Atriance
Other names506U78
AHFS/Drugs.comMonograph
MedlinePlusa607077
License data
Pregnancy
category
  • US: N (Not classified yet)
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailabilityn/a
Protein binding<25%
MetabolismBy adenosine deaminase, to 9-β-D-arabinofuranosylguanine
Elimination half-life30 minutes (nelarabine)
3 hours (ara-G)
ExcretionKidney
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC11H15N5O5
Molar mass297.271 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Nelarabine, sold under the brand names Arranon (US) and Atriance (EU), is a chemotherapy medication used for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).[1][2]

Nelarabine is a prodrug of arabinosylguanine nucleotide triphosphate (araGTP), a type of purine nucleoside analog, which causes inhibition of DNA synthesis and cytotoxicity.[3] Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In October 2005, it was approved by the FDA for acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least two chemotherapy regimens.[4] It was later approved in the European Union in October 2005.[2] It is available as a generic medication.[5]

References

External links